Physician profile
Mark J Wegmann
NPI 1114095965
$14,022.60
in general payments reported to CMS, 2019-2025
45 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $924 · 2021: $1,477 · 2022: $1,903 · 2023: $2,429 · 2024: $3,052 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,333 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,333.21 |
| Education | $117.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,599.99 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,334.21 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Janssen Biotech, INC. | $1,325.92 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $990.89 | 2019-2025 | Entyvio, Eohilia |
| Celgene Corporation | $722.63 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $615.67 | 2023-2025 | Ibsrela |
| Genzyme Corporation | $599.32 | 2023-2025 | |
| Pfizer INC. | $586.01 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $409.91 | 2023-2025 | Voquezna |
| Gilead Sciences, INC. | $405.47 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $271.53 | 2024-2025 | Dupixent |
| Allergan, INC. | $180.56 | 2019-2020 | |
| Lilly USA, LLC | $168.78 | 2024-2025 | Omvoh |
| Celltrion USA INC. | $162.59 | 2024-2025 | Vegzelma, Zymfentra |
| Aimmune Therapeutics, INC. | $157.90 | 2025 | Zenpep, Vowst |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$21,363.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Wegmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.